Andere talen Replimune Group, Inc.

Aandelen

REPL

US76029N1063

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
6,42 ^USD	+4,39%		-0,47%	-23,84%

08/04	Replimune Group geeft tussentijdse resultaten voor huidkankertherapie	MT
26/03	Replimune Group, Inc. Kondigt wijzigingen in het management aan	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Replimune Group Provides Interim Results for Skin Cancer Therapy	08/04
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting	07/04
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/04
Replimune : Uveal Melanoma Biomarker Poster at AACR 2024	01/04
Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions	26/03
Replimune Group, Inc. Announces Management Changes	26/03
Replimune Group, Inc. Announces CEO Changes, Effective April 1, 2024	26/03
Replimune to Present at the American Association for Cancer Research Annual Meeting 2024	06/03
Replimune to Present at Three Upcoming Investor Conferences	05/03
Replimune Group, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	08/02
Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update	08/02
Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference	28/12
Sector Update: Health Care Stocks Ease Late Afternoon	05/12
Sector Update: Health Care	05/12
Replimune Group Shares Slide as Trial of Skin Cancer Treatment Candidate Failed to Meet Primary Endpoints	05/12
Replimune's skin cancer drug fails in late-stage study	05/12
Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers	05/12
Replimune Group, Inc. Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failure Melanoma and Non-Melanoma Skin Cancers	05/12
Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research	08/11
Replimune Group Shares Fall After Fiscal Q2 Loss Widens; Company Sees Cash to Fund Operations Into H2 2025	07/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Replimune Group, Inc.

Aandelen

REPL

US76029N1063

Andere talen

Filters